NIHR | Health Protection Research unit in Antimicrobial Resistance and Healthcare Associated Infections at University of Oxford
The NIHR Health Protection Research Unit (HPRU) in Healthcare Associated Infections and Antimicrobial Resistance (AMR) is a partnership between Public Health England (PHE) and the University of Oxford in collaboration with University of Leeds, Animal and Plant Health Agency and European Bioinformatics Institute.
National Institute for Health Research (NIHR) has provided funding to establish 14 Health Protection Research Units (HPRU) to address key public health threats. The HPRUs are partnerships between Universities and Public Health England forming multi-disciplinary centres of excellence with a focus on collaborations and knowledge sharing.
HPRU in Healthcare Associated Infections and Antimicrobial Resistance at Oxford University is led by Professor Sarah Walker and our PHE lead is Dr Susan Hopkins.
The HPRU in Healthcare Associated Infections and AMR vision is to find better ways to manage and prevent threats from antimicrobial resistance and healthcare-associated infections, by detecting them faster, working out who needs protecting most and how this can be done.
It consists of 4 broad Research Themes:
NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance
We want to create opportunities for individuals to interact, engage and contribute to our research to: Improve its quality and relevance: Ensure our research questions align with the wider public’s priorities: Disseminate findings to everyone who may find them relevant, useful or interesting: Inspire adults and children and promote careers in research and Science, Technology, Engineering, and Mathematics
Our strategy for knowledge mobilisation/policy-maker engagement is based on PHE leaders being best-placed to ensure HPRU studies directly inform PHE needs and results are disseminated beyond academia, including into PHE guidance/outputs
Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial
Yu L-M. et al, (2021)
Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial.
Ramakrishnan S. et al, (2021), Lancet Respir Med
T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses.
Ogbe A. et al, (2021), Nature communications, 12
Niche and local geography shape the pangenome of wastewater- and livestock-associated Enterobacteriaceae.
Shaw LP. et al, (2021), Sci Adv, 7
20 October 2020
Two vital research programmes taking place at the University of Oxford may hold the key to understanding the immunity of recovered Covid-19 patients. The data will also be used by Professor Sarah Walker at the University of Oxford who is working with the Office for National Statistics on the COVID-19 Infection Survey.
12 October 2020
Prof Walker, Professor of Medical Statistics and Epidemiology at the University of Oxford’s Nuffield Department of Medicine, was recognised for services to academia and the COVID-19 response and will receive an OBE.
25 September 2020
Scientists from the University of Oxford’s Nuffield Department of Medicine have today published their evaluation of LamPORE, a novel diagnostic platform for detecting SARS-CoV-2 RNA. It combines loop-mediated isothermal amplification with nanopore sequencing. This technology has the potential to analyse thousands of samples per day on a single instrument.